Skip to main content
. 2019 Nov 28;47(3):713–720. doi: 10.1007/s00259-019-04584-1

Fig. 5.

Fig. 5

[68Ga]Ga-PSMA PET images of mCRPC patients before and after 3 cycles of PSMA-RLT: a patient with therapy response and PSA drop of about 70% (initial PSA 80.95 μg/L, after therapy PSA 22.95 μg/L); the arrows indicate residual metastatic areas. b Patient with therapy response and PSA decline of ≥80% (initial PSA 70.68 μg/L, after therapy PSA 6.4 μg/L)